Marilyn E. Levi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marilyn E. Levi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Adriana Weinberg
Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora
1 shared publicationB. K. Kleinschmidt‐DeMasters
Department of Pathology
1 shared publication- Carla C. Saveli
University of Colorado Denver, Department of Medicine, Division of Infectious Diseases, USA
1 shared publication Dianna Quan
Department of Neurology
1 shared publicationDonna J. Curtis
Division of Pediatric Infectious Diseases Childrens Hospital Colorado, Aurora, Colorado, USA.
1 shared publicationJeffrey H. Dunn
Department of Ophthalmology, Rocky Mountain Lions Eye Institute, University of Colorado School of Medicine, Aurora
1 shared publication
Latest Publications
- 19 April 2016
- Published by Wiley in Pediatric Transplantation
- Vol. 20 (6) , 744-746
West Nile infections in pediatric solid organ transplant recipients
- 19 April 2016
- Published by Wiley in Pediatric Transplantation
- Vol. 20 (6) , 744-746
West Nile infections in pediatric solid organ transplant recipients
- 15 November 2013
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 15 (6) , 478-485
West Nile Virus Infection in the Immunocompromised Patient
West Nile virus infection has become the predominant cause of flavivirus-associated encephalitis in the US. While 80 % of infected individuals are asymptomatic, 20 % develop symptoms including fever, headache, transient rash and gastrointestinal symptoms. Among the immunocompetent population, 1 in 150 develop neuroinvasive disease characterized by acute flaccid paralysis, Parkinsonian cogwheel rigidity, meningitis, encephalitis, meningoencephalitis and asymmetric muscle weakness (Mostashari et al. in Lancet 358:261–264, 2001). In the immunocompromised population such as transplant recipients and HIV-infected and chemotherapy patients, the incidence of neuroinvasive disease may be increased. The largest population studied is recipients of solid organ transplants, with data on both donor-derived and naturally occurring transmissions. The risk of neuroinvasive disease in donor-derived infection is estimated to be between 50 % and 75 % while in those with mosquito-borne transmission the risk is estimated at 40 % of those infected (Kumar et al. in Am J Transplant 4:1883–1888, 2004). With significant morbidity associated with donor transmission, specific pretransplant screening recommendations are reviewed. Treatment includes supportive care and consideration for the use of intravenous immunoglobulin.
- 15 November 2013
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 15 (6) , 478-485
West Nile Virus Infection in the Immunocompromised Patient
West Nile virus infection has become the predominant cause of flavivirus-associated encephalitis in the US. While 80 % of infected individuals are asymptomatic, 20 % develop symptoms including fever, headache, transient rash and gastrointestinal symptoms. Among the immunocompetent population, 1 in 150 develop neuroinvasive disease characterized by acute flaccid paralysis, Parkinsonian cogwheel rigidity, meningitis, encephalitis, meningoencephalitis and asymmetric muscle weakness (Mostashari et al. in Lancet 358:261–264, 2001). In the immunocompromised population such as transplant recipients and HIV-infected and chemotherapy patients, the incidence of neuroinvasive disease may be increased. The largest population studied is recipients of solid organ transplants, with data on both donor-derived and naturally occurring transmissions. The risk of neuroinvasive disease in donor-derived infection is estimated to be between 50 % and 75 % while in those with mosquito-borne transmission the risk is estimated at 40 % of those infected (Kumar et al. in Am J Transplant 4:1883–1888, 2004). With significant morbidity associated with donor transmission, specific pretransplant screening recommendations are reviewed. Treatment includes supportive care and consideration for the use of intravenous immunoglobulin.
- Open Access
- 1 July 2013
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 131 (7) , 958-960
Long-term Suppression of Multidrug-Resistant Cytomegalovirus Retinitis With Systemically Administered Leflunomide
Cytomegalovirus (CMV) infection continues to affect outcomes in transplant recipients. Typical CMV antivirals, including ganciclovir sodium and its oral prodrug valganciclovir hydrochloride, foscarnet sodium, and cidofovir, are DNA polymerase inhibitors. Resistance of CMV to this class of drugs is an ongoing challenge. Alternative CMV antivirals include leflunomide and cytomegalovirus immunoglobulin.1-3
- 1 July 2013
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 131 (7) , 958-960
Open AccessLong-term Suppression of Multidrug-Resistant Cytomegalovirus Retinitis With Systemically Administered Leflunomide
Cytomegalovirus (CMV) infection continues to affect outcomes in transplant recipients. Typical CMV antivirals, including ganciclovir sodium and its oral prodrug valganciclovir hydrochloride, foscarnet sodium, and cidofovir, are DNA polymerase inhibitors. Resistance of CMV to this class of drugs is an ongoing challenge. Alternative CMV antivirals include leflunomide and cytomegalovirus immunoglobulin.1-3
- Open Access
- 6 March 2013
- Published by Elsevier in American Journal of Transplantation
- Vol. 13 (s4) , 361-371
Arenavirus and West Nile Virus in Solid Organ Transplantation
- 6 March 2013
- Published by Elsevier in American Journal of Transplantation
- Vol. 13 (s4) , 361-371
Open AccessArenavirus and West Nile Virus in Solid Organ Transplantation
- 1 February 2011
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 44 (1) , 57-78
Oral Infections and Antibiotic Therapy
- 1 February 2011
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 44 (1) , 57-78
Oral Infections and Antibiotic Therapy
- 1 March 2010
- Published by Wiley in Clinical Transplantation
- Vol. 24 (2) , 223-228
Impact of rituximab‐associated B‐cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients
Levi ME, Quan D, Ho JT, Kleinschmidt‐DeMasters BK, Tyler KL, Grazia TJ. Impact of rituximab‐associated B‐cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant 2009 DOI: 10.1111/j.1399‐0012.2009.01044.x © 2009 John Wiley & Sons A/S.Abstract: Evidence suggests that West Nile virus (WNV) neuroinvasive disease occurs more frequently in both solid organ and human stem cell transplant recipients. The effect of concomitant anti‐B‐cell therapy with rituximab, a CD20+ monoclonal antibody, on WNV infection in this population, however, has not been reported. We describe a case of a patient with alpha‐1‐antitrypsin deficiency who underwent single lung transplantation in 2005 and was maintained on tacrolimus, cytoxan and prednisone. More recently, she had received two courses of rituximab for recurrent A2–A3 grade rejection with concomitant capillaritis and presented six months later with rapid, fulminant WNV meningoencephalitis. Her diagnosis was made by cerebrospinal fluid (CSF) PCR but serum and CSF WNV IgM and IgG remained negative. She received WNV‐specific hyperimmune globulin (Omr‐Ig‐Am®) through a compassionate protocol. She experienced a rapidly progressive and devastating neurological course despite treatment and died three wk after onset of her symptoms. Autopsy revealed extensive meningoencephalomyelitis.
- 1 March 2010
- Published by Wiley in Clinical Transplantation
- Vol. 24 (2) , 223-228
Impact of rituximab‐associated B‐cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients
Levi ME, Quan D, Ho JT, Kleinschmidt‐DeMasters BK, Tyler KL, Grazia TJ. Impact of rituximab‐associated B‐cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant 2009 DOI: 10.1111/j.1399‐0012.2009.01044.x © 2009 John Wiley & Sons A/S.Abstract: Evidence suggests that West Nile virus (WNV) neuroinvasive disease occurs more frequently in both solid organ and human stem cell transplant recipients. The effect of concomitant anti‐B‐cell therapy with rituximab, a CD20+ monoclonal antibody, on WNV infection in this population, however, has not been reported. We describe a case of a patient with alpha‐1‐antitrypsin deficiency who underwent single lung transplantation in 2005 and was maintained on tacrolimus, cytoxan and prednisone. More recently, she had received two courses of rituximab for recurrent A2–A3 grade rejection with concomitant capillaritis and presented six months later with rapid, fulminant WNV meningoencephalitis. Her diagnosis was made by cerebrospinal fluid (CSF) PCR but serum and CSF WNV IgM and IgG remained negative. She received WNV‐specific hyperimmune globulin (Omr‐Ig‐Am®) through a compassionate protocol. She experienced a rapidly progressive and devastating neurological course despite treatment and died three wk after onset of her symptoms. Autopsy revealed extensive meningoencephalomyelitis.
- Open Access
- 17 February 2010
- Published by MDPI AG in Infectious Disease Reports
- Vol. 2 (1) , 5-6
Ochrobactrum anthropi Septic Arthritis: Case Report and Implications in Orthopedic Infections
Ochrobactrum anthropi is a rare cause of orthopedic infections. We report the second case of Ochrobactrum anthrop septic arthritis in the literature. Our case highlights the ability of Ochrobactrum anthropi to cause septic arthritis and its relevance in the field of orthopedic infections.
- 17 February 2010
- Published by MDPI AG in Infectious Disease Reports
- Vol. 2 (1) , 5-6
Open AccessOchrobactrum anthropi Septic Arthritis: Case Report and Implications in Orthopedic Infections
Ochrobactrum anthropi is a rare cause of orthopedic infections. We report the second case of Ochrobactrum anthrop septic arthritis in the literature. Our case highlights the ability of Ochrobactrum anthropi to cause septic arthritis and its relevance in the field of orthopedic infections.